The gut microbiota and inflammatory bowel disease

Katsuyoshi Matsuoka, Takanori Kanai

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gut. Although the precise cause of IBD remains unknown, the most accepted hypothesis of IBD pathogenesis to date is that an aberrant immune response against the gut microbiota is triggered by environmental factors in a genetically susceptible host. The advancement of next-generation sequencing technology has enabled identification of various alterations of the gut microbiota composition in IBD. While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria. It has not yet been established how dysbiosis contributes to intestinal inflammation. Many of the known IBD susceptibility genes are associated with recognition and processing of bacteria, which is consistent with a role of the gut microbiota in the pathogenesis of IBD. A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.

Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalSeminars in Immunopathology
Volume37
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Inflammatory Bowel Diseases
Dysbiosis
Gastrointestinal Microbiome
Proteobacteria
Disease Susceptibility
Probiotics
Observation
Inflammation
Technology
Bacteria
Genes

Keywords

  • Crohn’s disease
  • Dysbiosis
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The gut microbiota and inflammatory bowel disease. / Matsuoka, Katsuyoshi; Kanai, Takanori.

In: Seminars in Immunopathology, Vol. 37, No. 1, 2015, p. 47-55.

Research output: Contribution to journalArticle

Matsuoka, Katsuyoshi ; Kanai, Takanori. / The gut microbiota and inflammatory bowel disease. In: Seminars in Immunopathology. 2015 ; Vol. 37, No. 1. pp. 47-55.
@article{e5de1ac773aa4e74a047c8b8ac4b5488,
title = "The gut microbiota and inflammatory bowel disease",
abstract = "Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gut. Although the precise cause of IBD remains unknown, the most accepted hypothesis of IBD pathogenesis to date is that an aberrant immune response against the gut microbiota is triggered by environmental factors in a genetically susceptible host. The advancement of next-generation sequencing technology has enabled identification of various alterations of the gut microbiota composition in IBD. While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria. It has not yet been established how dysbiosis contributes to intestinal inflammation. Many of the known IBD susceptibility genes are associated with recognition and processing of bacteria, which is consistent with a role of the gut microbiota in the pathogenesis of IBD. A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.",
keywords = "Crohn’s disease, Dysbiosis, Inflammatory bowel disease, Ulcerative colitis",
author = "Katsuyoshi Matsuoka and Takanori Kanai",
year = "2015",
doi = "10.1007/s00281-014-0454-4",
language = "English",
volume = "37",
pages = "47--55",
journal = "Seminars in Immunopathology",
issn = "1863-2297",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The gut microbiota and inflammatory bowel disease

AU - Matsuoka, Katsuyoshi

AU - Kanai, Takanori

PY - 2015

Y1 - 2015

N2 - Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gut. Although the precise cause of IBD remains unknown, the most accepted hypothesis of IBD pathogenesis to date is that an aberrant immune response against the gut microbiota is triggered by environmental factors in a genetically susceptible host. The advancement of next-generation sequencing technology has enabled identification of various alterations of the gut microbiota composition in IBD. While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria. It has not yet been established how dysbiosis contributes to intestinal inflammation. Many of the known IBD susceptibility genes are associated with recognition and processing of bacteria, which is consistent with a role of the gut microbiota in the pathogenesis of IBD. A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.

AB - Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gut. Although the precise cause of IBD remains unknown, the most accepted hypothesis of IBD pathogenesis to date is that an aberrant immune response against the gut microbiota is triggered by environmental factors in a genetically susceptible host. The advancement of next-generation sequencing technology has enabled identification of various alterations of the gut microbiota composition in IBD. While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria. It has not yet been established how dysbiosis contributes to intestinal inflammation. Many of the known IBD susceptibility genes are associated with recognition and processing of bacteria, which is consistent with a role of the gut microbiota in the pathogenesis of IBD. A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.

KW - Crohn’s disease

KW - Dysbiosis

KW - Inflammatory bowel disease

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84925486076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925486076&partnerID=8YFLogxK

U2 - 10.1007/s00281-014-0454-4

DO - 10.1007/s00281-014-0454-4

M3 - Article

C2 - 25420450

AN - SCOPUS:84925486076

VL - 37

SP - 47

EP - 55

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

SN - 1863-2297

IS - 1

ER -